The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
09/11/2009
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
W81XWH-09-LCRP-LCBRNA
Opportunity Category:
Discretionary
Posted Date:
Sep 11, 2009
Creation Date:
Sep 11, 2009
Original Closing Date for Applications:
Jan 06, 2010
Current Closing Date for Applications:
Jan 06, 2010
Archive Date:
Feb 05, 2010
Funding Instrument Type:
Cooperative Agreement
Grant
Category of Funding Activity:
Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards:
1
Estimated Total Program Funding:
$3,800,000
Award Ceiling:
Award Floor:
CFDA Number(s):
12.420
--
Military Medical Research and Development
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Agency Name
Dept. of the Army -- USAMRAA
Description
The LCRP Lung Cancer Biospecimen Resource Network (LCBRN) Award is intended to provide infrastructure support for the development of a lung cancer biospecimen resource that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human lung cancer biospecimens through a collaborative network across multiple institutions. The LCBRN will consist of a Coordinating Center that will also function as a biospecimen resource site and a minimum of two additional Biospecimen Resource Sites that will be jointly responsible for developing the biospecimen resource network for lung cancer research.
The Coordinating Center and Biospecimen Resource Sites must submit a single application. It is expected that the Coordinating Center will provide unique resources that may not necessarily be available at each Biospecimen Resource Site and can be leveraged for the LCBRN as a group. The types of lung cancer biospecimens for this proposal may be quite diverse. A list of possible biospecimens may include but are not limited to tumor tissue, matching uninvolved lung parenchyma or airway epithelium, lung exhalant, tissue, blood, sputum, hair, toenails, and bronchoscopic brushings and biopsies. Additional requirements for the LCBRN will be the ability to collect, store, and manage data derived from these biospecimens. LCBRN applicants should possess the ability to derivatize DNA, RNA, and proteins, and also utilize both standard and state-of-the-art technologies (e.g., laser capture microdissection, tissue microarrays) to provide the necessary biospecimen processing for lung cancer research studies.
The proposed LCBRN must collect, process, annotate, store, and distribute human lung cancer biospecimens that support two or more of the Areas of Emphasis listed below:
• Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer.
• Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors.
• Understanding the molecular mechanisms that lead to clinically significant lung cancer.
• Identification of the mechanisms that lead to the development of the various types of lung cancer.
• Identification of innovative strategies for prevention and treatment of early lung cancer.
• Understanding predictive and prognostic markers to identify responders and non-responders.
• Understanding acquired resistance to treatment. See the Program Announcement for the full Funding Opportunity Description.
Link to Full Announcement
If you have difficulty accessing the full announcement
electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org
CDMRP Helpdesk
Synopsis Modification History
There are currently no modifications for this opportunity.
